Clinical trials: Psychotic Disorder
Schizophrenia
A Clinical Pharmacology Trial of Brexpiprazole Long Acting Injectable (LAI) Administered as a Single Dose in Patients With Schizophrenia
The purpose of this study is to determine the pharmacokinetics (PK), tolerability and safety of brexpiprazole LAI following a single administration in subjects with schizophrenia.
- Trial name
- NCT05119894
- Testing
- Brexpiprazole LAI: Dose 1, Brexpiprazole LAI: Dose 2, Brexpiprazole LAI: Dose 3
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Schizophrenia
A Clinical Trial to Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
A clinical trial to study the efficacy and safety of an investigational drug in acutely psychotic people with schizophrenia. Participants in the study will either receive the drug being studied or a placebo.
- Trial name
- NCT04072354
- Testing
- SEP-363856 50mg, SEP-363856 75mg
- Where
- 53 sites in United States, Bulgaria and 4 more
- Volunteers
- 463 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Healthy
A 4-week Study of Mifepristone in the Prevention of Risperidone-induced Weight Gain in Healthy Male Volunteers
This is a 28-day, single-center, double-blind, placebo-controlled inpatient study of the administration of risperidone alone or in combination with mifepristone in healthy adult male volunteers to determine the average change in…
- Trial name
- NCT00698022
- Testing
- Risperidone, Mifepristone
- Where
- India
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Corcept Therapeutics
Schizophrenia
Safety and Efficacy of Zicronapine in Patients With Schizophrenia
To assess the effect of zicronapine versus risperidone on metabolic parameters comprising body weight, body mass index (BMI), waist circumference, levels of fasting blood lipids and glucose during 6 months of treatment.
- Trial name
- NCT01295372
- Testing
- Zicronapine, Risperidone
- Where
- 24 sites in Czechia, Estonia and 3 more
- Volunteers
- 160 people
- Sponsor
- H. Lundbeck A/S
Schizophrenia, Schizoaffective Disorder
Safety and Tolerability of BL-1020 in Hospitalized Subjects With Chronic Schizophrenia or Schizo-Affective Disorder
An open-label, multi-center, 6-week, sequential cohort study designed to determine the safety and tolerability of two dose ranges of BL-1020 in hospitalized subjects with chronic schizophrenia or schizo-affective disorder
- Trial name
- NCT00480571
- Testing
- BL-1020, BL 1020 High Dose
- Where
- 2 sites in Israel, Romania
- Volunteers
- 90 people
- Sponsor
- BioLineRx, Ltd.
Schizophrenia
A Pharmacokinetic and Safety Study of Risperidone Long Acting Injectable in Schizophrenic Patients
The purpose of this study is to explore the pharmacokinetic profile and safety after biweekly (every 2-week) intramuscular (IM) injections (6 injections) of risperidone long acting injectable 25, 37.5, or 50 mg/dose in…
- Trial name
- NCT00653406
- Testing
- Risperidone long acting injectable
- Volunteers
- 29 people
- Sponsor
- Janssen Pharmaceutical K.K.
Schizophrenia
Compare the Effects of Bifeprunox and Quetiapine on Weight Changes in Stable Schizophrenic Patients
The primary objective of the study is to evaluate changes in weight short and long term with bifeprunox and quetiapine. Study participation for the subject is 57 weeks.
- Trial name
- NCT00396214
- Testing
- Bifeprunox, Quetiapine
- Where
- 151 sites in United States, Argentina and 12 more
- Volunteers
- 83 people
- Sponsor
- Solvay Pharmaceuticals
Parkinson's Disease Psychosis
An Open-label Safety Study of Pimavanserin in Parkinson's Disease Patients
This is an open-label extension study to assess the long-term safety and tolerability of pimavanserin (ACP-103) in subjects with Parkinson's Disease Psychosis (PDP).
- Trial name
- NCT01518309
- Testing
- pimavanserin tartrate (ACP-103)
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Schizophrenia
Four Dimensions in Schizophrenia
Observational, non-interventional, longitudinal, prospective,multicenter, open label (No treatment is involved). 4 assessment will be carried out , in months 0, 1, 3 and 6.
- Trial name
- 4D (NCT00782899)
- Where
- 65 sites in Spain
- Volunteers
- 320 people
- Sponsor
- AstraZeneca
Schizophrenia
In-Patient Study In Schizophrenic Patients
This study is a placebo-controlled study to assess the safety and tolerability of a novel antipsychotic medication, (773812) when given to schizophrenic patients for twenty-eight days.
- Trial name
- NCT00197093
- Testing
- SB773812
- Volunteers
- 60 people
- Sponsor
- GlaxoSmithKline
Comparing Hospitalisation Time With Seroquel and Seroquel Prolong
Nis Register Study Comparing Seroquel and Seroquel Prolong
The general aim of this non interventional study is to clarify what are the current clinical treatment practices of Quetiapine Immediate Release and Quetiapine Extended Release.
- Trial name
- NCT00965536
- Where
- Finland
- Volunteers
- 200 people
- Sponsor
- AstraZeneca
Schizophrenia
Long-term Safety of SPD489 When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia
The primary purpose of this study is to determine if the long-term use of SPD489 (40, 80, 100, 120, 140, and 160mg) administered as a daily morning is safe and tolerable.
- Trial name
- NCT01760993
- Testing
- SPD489
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Shire
Quality of Life in Schizophrenia
Non-interventional Open Label Study to Investigate the Effect of Quetiapine XR on Patient Satisfaction and Quality of Life in Patients With Schizophrenia
Since subjective well-being and quality of life (QoL) are increasingly being recognized as important treatment outcomes in patients with schizophrenia (Hofer et al., 2004; Becker et al., 2005), the aim of this study is to…
- Trial name
- PASQAL (NCT00934726)
- Volunteers
- 150 people
- Sponsor
- AstraZeneca
Schizophrenia
Evaluation of Effectiveness and Safety of Paliperidone ER (Extended-release) Compared With Quetiapine in Patients With Schizophrenia
The purpose of this study is to evaluate the efficacy (effectiveness of drug) and safety of the antipsychotic paliperidone ER compared to another antipsychotic, quetiapine, and to placebo in patients who are acutely ill with…
- Trial name
- NCT00334126
- Volunteers
- 399 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
Seroquel on Glucose Metabolism
The purpose of this study is to determine whether six months treatment with the antipsychotic medicine Seroquel (quetiapine) may affect the schizophrenic patient's glucose metabolism
- Trial name
- NCT00214578
- Testing
- Seroquel (quetiapine)
- Where
- 70 sites in Bulgaria, Czechia and 7 more
- Volunteers
- 572 people
- Sponsor
- AstraZeneca
Schizophrenia
A Study of Paliperidone Blood Concentrations in Patients With Schizophrenia After Administration of Paliperidone Palmitate
The purpose of this study is to evaluate the concentration of paliperidone in the blood after intramuscular injection in upper arm (deltoid muscle) or in the buttock (gluteal muscle) in patients with schizophrenia.
- Trial name
- NCT01110317
- Testing
- paliperidone palmitate 100 mg
- Volunteers
- 49 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Schizoaffective Disorder
Acute Psychosis Treatment in the Long Term, Unitary Group Study (APLUS)
The purpose of this study is to prove safety and efficacy of aripiprazole.
- Trial name
- NCT00304655
- Testing
- Aripiprazole
- Where
- South Korea
- Volunteers
- 300 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Healthy
Study Of The PF-04958242 Blood Concentrations Of A Capsule Formulation Of PF-04958242 Compared To A Solution Formulation
This study will assess the relative bioavailability of a capsule formulation of PF-04958242, relative to a oral solution formulation of PF-04958242 in healthy adult subjects.
- Trial name
- NCT01646840
- Testing
- PF-04958242 capsule, PF-04958242 oral solution
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Biogen
Schizophrenia
Creating Live Interactions to Mitigate Barriers
This study is a validation study to evaluate the acceptability, feasibility and impact of a mobile psychosocial intervention to enhance social functioning in people with schizophrenia.
- Trial name
- CLIMB (NCT03317769)
- Testing
- Computerized Plasticity-Based Adaptive Cognitive Training, Commercially available computerized training, Optimized social skills training
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Posit Science Corporation
Schizophrenia
Study to Evaluate D2 Receptor Occupancy Following Single Intravenous Administration of ATI-9242
This study involves evaluating the occupancy of ATI-9242 at steady state at three different dose levels on D2 receptors in the brain using [18F] Fallypride PET in up to three cohorts of subjects.
- Trial name
- NCT02824666
- Testing
- ATI-9242, [18F]Fallypride Imaging
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Braeburn Pharmaceuticals